Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

1.9K
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
1.9K
Adrenergic Agonists: Therapeutic Classification01:18

Adrenergic Agonists: Therapeutic Classification

1.8K
Adrenergic agonists can be classified based on their therapeutic uses and mechanisms of action. They serve various purposes in clinical applications.
Vasopressor or pressor agents: They increase blood pressure and function as cardiac stimulants. Examples include endogenous catecholamines (norepinephrine and dopamine) and synthetic agents (phenylephrine).
Bronchodilators: β2-agonists can relax bronchial muscles and widen airways. They are commonly used for treating obstructive pulmonary...
1.8K
Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

2.1K
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
2.1K
Adrenergic Agonists: Direct-Acting Agents01:30

Adrenergic Agonists: Direct-Acting Agents

3.0K
Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
3.0K
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

1.6K
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
1.6K
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

1.3K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Agonist-specific conformational dynamics at the β<sub>2</sub>-adrenoceptor dictate allosteric modulation of Gαs signalling and bronchodilation.

British journal of pharmacology·2026
Same author

Longitudinal <sup>1</sup>H and <sup>129</sup>Xe Lung MRI in Patients With Post-COVID Residual Lung Abnormalities.

Journal of magnetic resonance imaging : JMRI·2026
Same author

Genome-wide association study of Idiopathic Pulmonary Fibrosis susceptibility using clinically-curated European-ancestry datasets.

The European respiratory journal·2026
Same author

Qualitative beta-2-adrenoceptor signaling in the regulation of human airway epithelia mucin and cytokine production.

Respiratory research·2026
Same author

Z variant heterozygosity in alpha-1 antitrypsin deficiency: disease risk and treatment implications.

Orphanet journal of rare diseases·2026
Same author

The Nottingham recovery from COVID-19 research platform (NoRCoRP): Functional, clinical and patient-reported outcomes in adults referred to a post-COVID respiratory service.

PloS one·2026
Same journal

Endothelial Cell Phenotypic Plasticity in Atherosclerosis.

Handbook of experimental pharmacology·2026
Same journal

Endothelial Dysfunction and Neurovascular Alterations in Autism Spectrum Disorder.

Handbook of experimental pharmacology·2026
Same journal

Molecular Mechanisms of Endothelial Shear Stress Mechanotransduction in Health and Disease.

Handbook of experimental pharmacology·2026
Same journal

Microvasculature of the Pancreatic Islets of Langerhans in Health and Diabetes.

Handbook of experimental pharmacology·2026
Same journal

Mechanisms of Actions of Physiological, Pharmacological, and Toxicological Dietary Bioactive Inorganic Boron.

Handbook of experimental pharmacology·2026
Same journal

BNCT Plus Luminescence: New Paradigm for Boron-Containing Drug Design.

Handbook of experimental pharmacology·2026
See all related articles

Related Experiment Video

Updated: Mar 11, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

32.6K

β2 Agonists.

Charlotte K Billington1, Raymond B Penn2, Ian P Hall3

  • 1Division of Respiratory Medicine, University of Nottingham, Nottingham, NG7 2RD, UK.

Handbook of Experimental Pharmacology
|November 24, 2016
PubMed
Summary
This summary is machine-generated.

Beta agonists have been used for 5,000 years to treat asthma and COPD. Future research on beta2 adrenoceptor genetics and pharmacogenetics may improve these vital bronchodilator therapies.

Keywords:
Airway smooth muscleAsthmaCyclic AMPIsoprenalineβ adrenoceptorβ agonists

More Related Videos

In vitro Measurements of Tracheal Constriction Using Mice
10:20

In vitro Measurements of Tracheal Constriction Using Mice

Published on: June 25, 2012

21.4K
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

41.7K

Related Experiment Videos

Last Updated: Mar 11, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

32.6K
In vitro Measurements of Tracheal Constriction Using Mice
10:20

In vitro Measurements of Tracheal Constriction Using Mice

Published on: June 25, 2012

21.4K
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

41.7K

Area of Science:

  • Pharmacology
  • Respiratory Medicine
  • Genetics

Background:

  • Beta agonists are the primary treatment for asthma and chronic obstructive pulmonary disease (COPD), with a history spanning 5,000 years.
  • Current beta agonists, developed over a century of research, include long-acting for prophylaxis and short-acting for acute relief of bronchoconstriction.
  • Despite their efficacy, safety concerns exist, including a black box warning for long-acting beta agonists in asthma and a significant number of patients with uncontrolled asthma.

Purpose of the Study:

  • To discuss the historical evolution of beta agonist use in respiratory diseases.
  • To explore the understanding of beta agonist actions on airway smooth muscle for future drug improvement.
  • To examine the role of beta2 adrenoceptor genetics and pharmacogenetics in clinical outcomes.

Main Methods:

  • Review of historical data on bronchodilator use.
  • Analysis of the mechanism of action of beta agonists on airway smooth muscle.
  • Discussion of genetic research on the beta2 adrenoceptor and its clinical implications.

Main Results:

  • Beta agonists have a long history of use and remain central to asthma and COPD management.
  • Understanding drug-target interactions is key to improving beta agonist efficacy and safety.
  • Pharmacogenetics offers insights into individual responses to beta agonist therapy.

Conclusions:

  • The evolution of beta agonists highlights ongoing efforts to optimize respiratory disease treatment.
  • Future advancements may stem from a deeper understanding of beta2 adrenoceptor genetics and personalized medicine approaches.
  • Continued research is essential for improving therapeutic outcomes for patients with asthma and COPD.